Jacobson Pharma Corporation Limited (2633.HK)
HKD 1.01
(0.0%)
HKD 1.01
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 749.37 Million HKD | -53.14% |
| 2022 | 1.59 Billion HKD | 13.41% |
| 2021 | 1.4 Billion HKD | -14.48% |
| 2020 | 1.64 Billion HKD | 0.03% |
| 2019 | 1.64 Billion HKD | 27.05% |
| 2018 | 1.29 Billion HKD | -4.04% |
| 2017 | 1.35 Billion HKD | 44.12% |
| 2016 | 938 Million HKD | 112.92% |
| 2015 | 440.54 Million HKD | -7.98% |
| 2014 | 478.74 Million HKD | 55.6% |
| 2013 | 307.67 Million HKD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 Q2 | 1.32 Billion HKD | 0.0% |
| 2023 FY | 749.37 Million HKD | -53.14% |
| 2023 Q4 | 749.37 Million HKD | 0.0% |
| 2022 Q4 | 1.59 Billion HKD | 0.0% |
| 2022 FY | 1.59 Billion HKD | 13.41% |
| 2022 Q2 | 1.55 Billion HKD | 0.0% |
| 2021 FY | 1.4 Billion HKD | -14.48% |
| 2021 Q4 | 1.4 Billion HKD | 0.0% |
| 2021 Q2 | 1.41 Billion HKD | 0.0% |
| 2020 Q4 | 1.64 Billion HKD | 0.0% |
| 2020 FY | 1.64 Billion HKD | 0.03% |
| 2020 Q2 | 1.64 Billion HKD | 0.0% |
| 2019 Q4 | 1.64 Billion HKD | 0.0% |
| 2019 FY | 1.64 Billion HKD | 27.05% |
| 2019 Q2 | 1.55 Billion HKD | 0.0% |
| 2018 Q4 | 1.29 Billion HKD | 0.0% |
| 2018 Q2 | 1.27 Billion HKD | 0.0% |
| 2018 FY | 1.29 Billion HKD | -4.04% |
| 2017 Q2 | 949.59 Million HKD | 0.0% |
| 2017 FY | 1.35 Billion HKD | 44.12% |
| 2017 Q4 | 1.35 Billion HKD | 0.0% |
| 2016 Q2 | 644.55 Million HKD | 0.0% |
| 2016 FY | 938 Million HKD | 112.92% |
| 2016 Q4 | 938 Million HKD | 0.0% |
| 2015 FY | 440.54 Million HKD | -7.98% |
| 2015 Q4 | 440.54 Million HKD | 0.0% |
| 2014 FY | 478.74 Million HKD | 55.6% |
| 2014 Q4 | - HKD | 0.0% |
| 2013 FY | 307.67 Million HKD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 6.8 Million HKD | -10904.099% |
| Grand Pharmaceutical Group Limited | 3.4 Billion HKD | 77.987% |
| Extrawell Pharmaceutical Holdings Limited | 120.41 Million HKD | -522.356% |
| Wai Yuen Tong Medicine Holdings Limited | 460.94 Million HKD | -62.573% |
| Qianhai Health Holdings Limited | 487 Thousand HKD | -153776.591% |
| Lee's Pharmaceutical Holdings Limited | 204.14 Million HKD | -267.091% |
| Essex Bio-Technology Limited | 294.02 Million HKD | -154.872% |
| Tongfang Kontafarma Holdings Limited | 333.82 Million HKD | -124.484% |
| PuraPharm Corporation Limited | 424.77 Million HKD | -76.42% |
| SSY Group Limited | 3.37 Billion HKD | 77.79% |
| JBM (Healthcare) Limited | 133.4 Million HKD | -461.724% |
| China Resources Pharmaceutical Group Limited | 85.84 Billion HKD | 99.127% |